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The BP180 antigen, a cornponent of the epidermal 
anchoring complex, has been identified as one of the 
major antigenic targets of autoantibodies associated with 
the blistering skin disease, bullous pemphigoid. Our 
research group has recently den1onstrated that reactivity 
ofbullous pemphigoid autoantibodies to the BP180 ecto-
dornain is almost entirely restricted to a set of four 
antigenic sites clustered within the tnen1brane-proxitnal 
noncollagenous stretch (NC16A). Using a passive transfer 
n1ouse n1odel, antibodies to the corresponding noncolla-
genous region of murine BP180 were shown to trigger 
an inflammatory subepidertnal blistering disease that 
closely mimics bullous pemphigoid. We now report the 
developtnent of an enzytne-linked itnmunoabsorbent 
assay system that is extremely · sensitive in detecting 
disease-specific autoantibodies in the sera of bullous 
pemphigoid patients. The target antigen in this assay is 
a recombinant form of the BP180 NC16A domain that 
B ullous pemp higoid (BP) is a subepidermal autoimmune blistering disease first described by Lever (1953) . Th is disease primarily afFects the .elderly and is characterized by the linear deposition of lgG and C3 at the cutaneous basement memb rane zone (BMZ) Qordon ct a/, 1967). 
Autoantibodies in .BP are directed to tvvo pro teins associated with the 
anchorin g complex, BP230 and BP1 80, also known as BPAG 1 and 
.BPAG2, respectively (Stanley et a/, 1981; La bib et a/, 1986; Stanley 
et a/, 1988; Mu eller et a/, 1989; Diaz et al, 1990; Giudice et a/, 1992). 
.BP230 localizes to the in tracellular hemidesmosomal plaque (Tanaka 
ct a/, 1991), w hereas .BP180 is a transmembra ne glycoprotein whose 
extracell ula r doma in consists of 15 interrupted collagen domains 
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contains all four of the well-defined bullous pemphigoid-
associated antigenic sites. OfSO randmnly selected bullous 
pemphigoid sera tested, 47 (94%) were positive in this 
assay, whereas no specific reactivity was detected in any 
of tl1e 107 controls. Interestingly, all three of tl1e bullous 
pemphigoid sera that were negative in tl1is assay had been 
obtained from patients who were already undergoing 
treatment. The NC16A enzyme-linked immunosorbent 
assay is more sensitive than any of the standard techniques 
for detecting circulating bullous pemphigoid autoanti-
bodies, including other enzyme-linked immunosorbent 
assays, in1n1unoblotting, and indirect imtnunofluores-
cence. Finally, the NC16A enzyme-linked immunosorb-
ent assay provides immunologic information that cannot 
be obtained fron1 direct inununofluorescence studies of 
skin biopsies, and that may well be relevant in the 
diagnosis and treatment of bullous petnphigoid. Key 
wm•ds: autoantigen/ collage11! epitopelhem.idesmosome. J I1west 
Demw.tol 109:679-683, 1997 
(G iudice e/ a/, 1992; Li ct a/, 1993). In addition to BP, autoantibodies 
to .BP180 have been found to be associated with t\vo other subepithelial 
blistering diseases, herpes gesta tionis and cicatricial pemphigoid (G iudice 
et a/, 1993; .Balding et a/, "1996) . T he pathogenic relevance of anti-
.BP180 antibodies has been established using a passive tran sfer mouse 
model (Liu cl al, 1993, 1995) . Rabbits were immunized with a 
recombinant fo nn of murine .BP180 and the pu rified ra bbit lgG was 
inj ected into neonatal tnice. T he antibody-trea ted mice developed a 
subepidenna.l blistering disease that duplicated the key features of BP, 
i.e., IgG and C3 deposition at the BMZ, inflammatory infiltration of 
the upper derm is, and detachment of the epidermis from th e basement 
membran e. 
Epitope mapping studies of humaJl .BP180 have shown that the 
NC 16A domain of this protein harbors all of the n1.ajor extracellular 
antigenic sites recognjzed by .B P sera (G iudi ce et a/, 1993; Zill ikens 
et a/, 1997). Immunoreactivity of .BP sera to the BP180 ectodomain 
can be abolished by depletion of autoantibodies to the BP180 NC16A 
domaj n. lt was further shown tbat NC16A contains four distinct 
an tigeni c sites recognized by .BP autoa ntibodi es. Interestingly, all tom 
sites are clustered within the N-terminal 45 amino acid stretch of this 
noncollageno us exu·acellulaT domain . .By immunoblotting, 15 of 15 BP 
sera reacted with a bacte ria.! fu sion protein contai ning this 45 amin o 
ac id stretch of N C l 6A (ZiUikens et a/, J 997). 
A previous enzym e-linked inm1llnosorbent assay (ELISA) for BP180 
autoantibodies used a recombinant form of NC16A consisting of 
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Figure L Schematic diagram showing the segments of human BP180 
present in the recombinant proteins GST-NC16Al-5 (used in the 
present E LISA) and GST- NC16A2-4 (used in a previous ELISA). T M , 
transmembra ne domain ; n, extracellular coUagenous domains of the human 
BP I SO protein. Ovals la beled "0," "1," "2," and "3" represent the fo ur epi topes 
that have been identified within the N-tenn inal 45 amino acids of the J3P1 80 
NCl6A domain (Z illi kens et a/, 1997) . T he entire NCl 6A domain is present 
in the GST-NC16A "I- 5 fusion protein , whereas GST-NC16A2-4, used in a 
previo usly reported ELI SA (G iudice cr a/, 1994) , conta ins onl y three of the 
fo ur well-characterized UP-associated epitopes. 
42 ami n o acids (G iudi ce et a/, 1994) . T he assay de tected BP1 80 
autoantibo dies in 53% of BP sera. T he recombinant prote in used in 
this ELI A lacked th e N-terminal 17 anti no acids o f N C 16A , a stre tch 
con taining o ne of the recentl y de fin ed antigeni c si tes, and on e that is 
recogni zed by 60% of BP sera by immuno blo tting (Zillike ns et a/, 
1. 997). T he aim of th e curren t study was to d evelo p a highl y sensitive 
E LISA fo r the detectio n of au toa n tibodies to B P 180 using a recombinant 
fo rm of full - leng th NC16A , w hich en compasses all fo ur o f the well-
defi ned antigenic sites associa ted with BP. 
MAT ER.JALS AND METH O DS 
Patients and sera Serum samples were obta ined from 50 we ll-characteri zed 
BP patients. In 22 cases, the sample was obtai ned before treatment was ini ti ated, 
whereas 12 patients were under therapy at the time of the blood draw. 
ln fo nnation on treatment was not ava ilable in the remaining cases. All UP 
patients had linear de posit< o f C3 and/or lgG at the DMZ in perilesional skin 
biopsies by direct im munoflu orescence (IF) assays. By indirect IF analysis on 
1 M Na !-sepa rated human skin (Gammon cr a/, 1984; Z illikens e/ a/, 1996) , 
42 BP sera showed lgG reactivity with the epidermal side o f the split, w hereas 
the remaining eight were negative. Contro ls (n = 1 07) incl uded sera fi·o m 
pati ents with ep ide rmolysis bullosa acquisita (EBA; n = "12), pemphigus vulga ris 
(PV; n = I H) , the Brazili an endemic fo rm of pemphigus fo liaccus [also known 
as fogo sclvagem (FS; n = 30)"J, and hea lthy vo lunteers (n = 47). All EJ3A se ra 
had circul ating autoa ntibodi es binding exclusively to the dermal side o f the 
sp li t, and ·1 0 of the 12 EBA sera reacted with the 290-kDa EBA autoantigen 
by im munob lotti ng. All PV and FS se ra yielded th e typical intercellular stai ning 
patte rn by indirect IF on monkey esophagus and lwman neonatal fo reskin, 
respectively. All 15 of the PV sera that were tested by inununoprecipitation 
showed reactivity with the extracellular domai n of desmoglein 3. All FS se ra 
irn mu noprec ip itated bovine desmoglcin "I as descri bed prev iously (Olague-
Alca la er a/, 1994) . 
Preparation of recombinant proteins A DNA segment encoding the 
enti re NC16A do main was obtained by polymerase chain reacti on ampli fication 
using a previously cloned hu ma n J3P1 80 eDNA as template (Giudice ct a/, 
1992; Z illi kens cr nl, 1997). 'The ampli fica ti on product was subcloned into 
pGEX- 1 T (Pharmacia, Pisca taway, NJ ) using an enginee red Notl site. T he 
resul ti ng glu tathione - transferase (GST)-N C 16A :I -5 fusion prote in and recom-
binant GST were expressed in bscherichi11 coli strain D l-1 50'. and puri fied by 
gluta thione-agarose affi ni ty chromatograph y, as described previously (G iudice 
et a/, 1993). T he recombinan t form of N C 16A used in this E LISA is shown 
in Fig 1. 
I.tnmunoblotting of recombinant proteins and skin extrac ts Sodium 
dodecyl sul f.1te polyacrylamide gel electrophoresis (SDS- PAGE) and immunob-
lotting were perfo rmed as described (Giudice et a/, "1 993). Affiniry purified 
recombinant prote ins were fractionated by 15% SDS-PAGE. Epidennal and 
de nnal extracts were prepared as described (Labib et a/, 1986; Bernard cr a/, 
"1990), and fractionated by 6% and 5% SDS-PAGE, respecti vely. Sera of patients 
and controls we re preadsorbed with a bacte ri:tl cel.ll ysate containing recombinant 
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GST to eliminate reacti vity with the GST moiety of the fusion pro tein and 
used at a 1 00-fold dilution. lnumrnoadsorptions were verified to be complete 
by the absence of reactivity with recombinant GST. 
ELISA protocol In the ELI SA used in this stud y, immobilized GST-
N C 16A1 -5 was probed with a series ofBP and control sera using a horseradish 
perox idase-conjuga ted secondary antibody. As a background contro l, the same 
se ra were tested fo r reacti vity with a molar eq ui va lent amount of GST. The 
entire assay was performed at room tempera ture on 96-well microtiter plates 
(fmmul on 4, Dynatech, C hanti.l.l y, VA). 
D efinin g the optimal wo rking conditions of the assay followed establi shed 
guidelines (Kemeny, 1991; C rowther, 1995). C hessboard titrations were per-
formed with serial dilutions of antigen (3.2 !lg to 3. ·1 ng) and secondary 
antibody (500-64,000-fold dilutions) and a constant 1 00-fold dilution of a 
primary antibody (a BP serum wi th medium range reacti viry to B P1 80). Analysis 
of the curves generated by plotting antigen concentration versus 00492 revealed 
tha t a 10,000-fold dilu tio n of the secondary antibody produced opti mal 
discriminati on in this assay. Lower dilu tions of secondary antibody resul ted in 
an increase in background labeling, higher dilu tions resulted in a loss o f 
sensitivity. ln a sirn ilar fashi on, chessboard titrations were performed with se ri al 
dilutions of antigen (3.2 !lg to 3.1 ng) and prinmy anti body (25-3200-fold 
dilutions of a BP serum) and a constant 1 0,000-fold dilu tion of the secondary 
antibody. Analysis of the plot o f antigen concentration 11ers11s primary antibody 
dilution revealed that a 200-fold dilu tion of the primary antibody yielded the 
highest level of discrimination. T he data also showed that maximal levels of 
ta.rge t antigen we re adsorbed when 400 ng of GST-N C l6AJ-5 were appli ed 
to each well. Coa ting of wells at 4°C overnight did not noticeably alter the 
amo unt of antigen adsorbed. 
T he optimized ELI SA was run under the fo llowing condi tions. Each well 
was coated for 2 h with 400 ng of purified recombinant GST- NCl6A1-5 in 
50 IJ.I o f 0. 1 M bica rbonate buffe r, pH 9.6. Wells were then washed fi ve times 
with phosphate-buffe red saline (PBS), pH 7.2, using an automated microplate 
washer (model 1550, Biorad, Richmond, CA) , and blocked fo r 1 h with "100 111 
PBS contai ning 1% bovine serum albu min (BSA; Sigma, St. Louis, MO). 
Subsequentl y, wells were incubated for 1 h with 50 111 of a primary serum (BP 
or control) dilu ted 200-fold in PBS comaining 1% BSA and 0.05% Tween-20. 
Afte r was hing as above, each well was incubated for l h with 50 111 horseradish 
peroxidase-labeled goat anti- human lgG (Kirkegaard and Peny, Gaithersburg, 
M D) diluted 1 0,000-fold in PBS with 1% BSA and 0.05% Tween-20. l'o ll owing 
another series of washes, 50 ~ll of substrate solution (a-phenylenediami ne in 
0. 1% H20 2) were added to each wel l. Ten min after substrate addition, the 
reaction was stopped by the addition of 50 ~tl 2N H2S04, and the O D4n was 
measmed using a microplate reader (model 2550; Bior·ad). Each serum was 
assayed in tri plica te for reactivity with both GST- NC 16A 1-5 and recombinant 
GST. Fo r each se rum tested, the mean optica l density (O D) reading obtai ned 
with GST was subtracted fro m the mean reading obtained with GST-
NC16A1-5. 
In order to minimize plate-to-plate n riabili ty, the ELISA va lue of each 
se rum on a plate was adjusted relative to a standard curve generated fi·om the 
.ELI SA resul ts of one negative reference serum and three seri al dilutions of a 
13P- positive reference serum. A two piece linea r spline (Ertel and Folkes, "1976) 
was fi t to the data to prov ide this adjustment. As applied here, the piecewise 
linear spline is the best least squares fi t o f two stra ight line segments to the 
reference da ta for aU plates. Use of such a spline prov ided a slightly better fit 
to the reference data over using a single straight line. T he jo in po int (knot) of 
the spline was chosen to be 0.612 O D units in orde r to maximize the prec ision 
of the sta nda rd curve over the range of 0-0.612 OD units, ~ range that 
encompasses aU of the control data and the lowest readin gs fi·om the 13P group. 
Based on the resul ts from the internal standards, OD readings showed a linea r 
response up to a va lue of ·1.5 O D units. Sera that yielded va lues higher than 
1.5 OD units were retested at higher di.lutions until readings within the linea r 
range were obtained. 
R ES ULTS 
The NC16A ELISA is a highly sensitive technique for detecting 
anti -BP180 autoantibodies in the sera of BP patients A large 
number o f BP and contro l se ra were tested for reac ti vity w ith the 
BPJ 80 N C 16A domain using th e abo ve-described ELI SA p rotoco l. 
To establish th e backgro und cut-off fo r this assay, a statistical an alysis 
was perfo nned o n the N C 16A E L ISA results o bta in ed w ith the fo ur 
contro l groups (E BA, FS, PV, and norm al human se ra). A o n e- way 
analysis of va ri ance sho w ed no signifi cant differen ce in the m ean 
O D 492 read ings o b ta ined fro m these four groups (p = 0 .1 8). A ccording 
to the R yan-J o iner test fo r n o rmali ty (Shapiro and W ilk , 1963), OD4n 
readings 6.-o m th e fo ur individual contro l groups, as w ell as the po oled 
data fi·om these gro ups , were consistent w ith a Gaussian distributio n 
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Figure 2. The NC16A ELISA is a specific and sensitive tool for the 
diagnosis ofBP. 13P and control sera [fi·orn patients with ep idermolysis bullosa 
acq uisita (EBA), pemphigus vu lga ris (PV), fogo selngem (FS) , and he;~lth y 
co ntro ls (NHS)J weno incubated at a 200-fold dilu tion with immobili zed 
NC 16A-GST fusion prote in and recombinant GST. Each se rum was tested in 
triplicate with both proteins and the plo tted points represent the difFerence of 
the means of the OD-192 readings obta ined with GST-NC16A l -5 and 
recombinant GST. .. .. .... , cut-ofJ o f the assay (mean OD4n of pooled contro ls 
+ 3S D). 
(p = 0.40 for the pooled data). T he rJw data from each plate were 
adjusted using a linea r spline as described in Materials a111l Met/10ds. T he 
mean of the adjusted data fi·om the 107 control sera was 0. 168 with a 
standard deviation of 0.089. T he cut-o lf for the NCl6A ELISA was 
set at 0.443 OD units (a z-valu e of 3.08), which yielded an observed 
specifi city of 100% (none of the I 07 co ntrols exceeded this v~tlue) and 
a th eoretical specifi city of 99 .9')1, (i. e., based on the observation that 
the control data are normally distlibuted, one control serum in 1000 
is predicted to exceed this cut-off). Variability of the results of this 
assay was established by calculating the coeffi cient of variance exhibited 
by an .intemal reference BP serum with an intermediate OD reading. 
The unadjusted OD readLngs showed a 15.3% variance between runs 
and a 10.7% variance between plates on a given wn . After adjustment 
of the data based on th e internal standard curves, the coefficients of 
variance were reduced to 3.9% and 1.0% for the run-to-run and plate-
to-plate compatisons, respectively. 
As shown in Fig 2, 47 of the 50 BP sera included in this study 
(94%) exh.ibited specific reactivity with NC16A. Any se ra that yielded 
OD492 readings higher than 1.5 at the standard 200-fo ld dilution were 
diluted furth er to obtain readings within the linear range of the plate 
reader. Twenty-two of the 50 BP sera were obtain ed during the early 
stage of the disease before any treatment was initiated. In al l of these 
sera , BPlSO autoantibodies were detected by E LI SA. Of the 12 sera 
that were co llec ted during th erapy, nine sa mples contained anti -B P1 80 
antibodies, and three sera had readings below the cut-o B:~ Two of the 
ELISA-negative sera were from patients who had been undergoing 
treatment with oral corticosteroids for 3 and 7 mo. T he third BP 
patient, whose serum fe ll below the ELISA cut-off, had been treated 
with tetracycline and niacinamide for 8 mo. All three patients still had 
sk.in lesions at the tim e serum samples were obtained. For 16 of th e 
BP sera included in th is study, no information was availab le as to 
whether the blood had been drawn before or during trea tment. Ali 16 
sera in this last group, however, were positive by ELISA. 
Detection of circulating BP autoantibodies by the NC16A 
ELISA is more sensitive than immunoblotting or indirect 
in~tnunofluorescence techniques Forty- fi ve of the 50 BP sera in 
this study (90%) showed specifi c reactivity with the GST-NC16A 1-5 
fusion protein by inm1unoblo tting. Three of the five BP sera that 
failed to react with NC16A by immunoblotting were positive in the 
NC16A ELISA. O n the other hand, one BP serum that fell below the 
cut-off in the NC16A ELISA showed specific rea ctivity with N C 16A 
by immunoblotting (Table 1). 
ELISA FOR DETE T ION OF ANTI-BI' ISO ANTffiODIES 681 
When tested by immunoblott.ing against a human epidenna.l extract, 
29 of the 50 BP sera (58'X•) reacted with BP180, and all of these 
BP180-positive sera were also positive in the N C I6A ELISA. Thirty 
of the 50 B P sera (60%) contain ed autoantibody reactivity to the 
BP230 antigen , as d termined by immunoblotting using a human 
epidermal extract. Interes tingly, all three of th e BP sera that were 
negative .in the N C 16A ELISA did react with BP230 by immunoblot-
ting. Representative immunoblot labeling patterns fo r BP sera are 
shown in Fig 3. The immunobl ots in the left and midc!Je panels of 
tllis figure show reacti vity with GST-NCI 6A 1-5 (la11es 2 ~nd 4) , but 
only the blot on th e left shows reactivity with epidermal BP1.80 (la11e 
"/) . T he serum that was used to label the immunoblot on the right 
reacts with epidermal BP230 (la11e 5), but does not recognize epidem1al 
BP"ISO (la11e 5) or the GST-NC:I6Al -5 fusion protei n (la 11 c 6) . 
By indirect IF on salt-split sk.in, 42 of th e 50 BP sera (84%) 
contained autoantibodies binding to the epidermal side of th e plit. 
lmmunoblotting revealed that, of the 42 sera positive by indirect IF, 
28 reacted witl1 epidermal BP230, 25 reacted with BP180 from an 
ep.idermal extract, and 37 reacted with the GST-NC16Al-5 fus.ion 
protein by immunoblotting. Also among the BP sera that showed an 
ep.idenn a.l-side lf labeling pattern on salt-split skin were two that had 
no detectable anti-BP180 autoantibodies, as determined by the N C16A 
ELISA or immunoblotting with either recombinant or tissue-derived 
BP180. Both of these BP !SO-negative sera contained autoantibodies 
that recognized BP230 by immunoblotting, and both serum samples 
had been obtained while the patients were undergoing therapy. Among 
the eight sera that exhibited no labeling by indirect IF at a diluti on of 
·1 :20 were two that reacted with BP230 and four that reacted with 
BP180 by immunoblotting ·with an epidennal extract. All eight of 
the indirect IF-negative BP sera reacted with GST-NC J6A 1-5 by 
immunoblotting, and seven were positive in the NC16A ELI SA. 
D l C USSION 
In this paper, we report the development and characterization of a 
highly specific and sensitive ELI SA for the detection of autoantibodies 
to BP180 in the sera of patients with BP. T he recombinant fmm of 
BP1 80 that was used in this study contained all of the major extracellular 
epitopes recognized by autoantibodies in BP sera , as defined in a recent 
epitope mapping study by our group (Zillikens ct al, 1997). In this 
ELISA system ,' autoantibodies to the BP180 NC16A domain were 
detectable in 47 of the 50 BP sera tested. T he overall sensitivity of the 
assay was 94%, at a c~Jcu lated speci.ficity of 99.9%. 
Other previously reported ELI SA systems designed to detect circulat-
ing BP autoantiboclies show much lower levels of sensitivity co mpared 
with the present NC16A ELI SA . Ide et a/ (1. 995) developed an ELISA 
us.ing recombinant forms of the C-tenninal domain of mur.ine BP230. 
Approximately 50% ofBP sera reacted with these recombi nant proteins 
by immunoblotting, and most of th e immunoblot-positive sera al~o 
recognized the proteins by ELISA. Another recent ELISA study reports 
a sensitivi ty of62'X> for the detect.ion oflgE antibodies to a recombinant 
form of BP230 (Delaporte et a/, 1996). O ur laboratory previously 
described an ELISA in which 53% of BP sera showed reactivity with 
a recombinant fo rm ofBP180 (G iudice el a/, 1 994). T he recombinant 
protein used in this prev.ious assay (designated GST-SD-1 or GST-
NC 16A2-4) contain ed a 42 amino acid segment ofNC16A, but lacked 
the N-tenninal 17 ant.ino acids of this B P"J 80 domain. [n a recent 
epitope mapping study, this 17 amino acid stretch of the BP180 
ectodomain was found to contain an antigenic site recogni zed by 60% 
of BP sera (Zi llikens et a/, 1997) . Of 1.5 BP sera tested, t"\¥0 reacted 
with this stretch and no other site within N C16A. Inclusion or 
exclusion of this short stretch of BP180 may well account for at least 
part of the large difference in sensitivity levels exhibited by the NC16A 
and the N C J 6A2-4 ELISA protocols (94% 11s 53%) . T he enhanced 
sensitiv.ity and specificity of the present ELISA can also be attributed 
to several other alterations made in the parameters of the assay that 
were based on a rigorous and systematic optimization strategy, including 
chessboard titrations of serial antigen conce ntrations, serum dilutions, 
and conjugate d.ilut.ions. 
Compared with clirect IF analysis of skin biopsies from patients (for 
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Table I. Detection of autoantibodies in BP sera by the NC16A ELISA is more sensitive than in1.munoblotting and indirect IF 
i111111lll10biotting IICYS IIS 
GST-NC l 6A J-5" 
lmmunoblotting ''ersus human c pid e rt1l :ll ex tr:lct1' 
1\.eoctivity with 13P'I SO 1\.cactivity with BP230 I ndin:ct IF Iabding of so lt- split ski n' 
Pos Neg Pos 
NC I6A ELI SA 44 3 29 
Positive (n = 47) 
NC16A ELISA 2 0 
Negative (n = 3) 
TOTA L 45 5 29 
Neg Pos 
IS 27 
3 3 
2 1 30 
Neg 
21J 
() 
20 
Epidcrmol side 
40 
42 
Dcrn1:1 l side Neg 
() 7 
0 
() 8 
"l3 1) sera (diluted 1(10-fold and prc::1dsorbt!d aga inst recombinant GST) were tested for reactivity \Vith afEniry pu rified GST-NCIGA I-5 0 11 i lll lllunoblots. 
"UP !icra were used ru a I 00-fo ld dilu tion. 
t l M NaCI-scparatcd hum;m skin was incubated w ith a I :20 dilutio n of paticn rs' sera, followed by an in cubatio n wirh flu orescei n isothi ocya n:m.:.- labdcd goat ~mri-humau lgG. 
200-
-66 
-45 
-31 116-
-21 
1 2 3 4 5 6 
Figure 3. Three representative imJ111.1110blot labeling patterns exhibited 
by DP sera. lmmunoblots conta ining an epidermal pro tein ex tract (lan es 1-3) 
and recombinant GST-NC 16A 1-5 (la11cs 4-6) were bbcled with three UP se ra. 
O ne 13P serum reacted with both the epidennal-deri ved md the recombinant 
f01111 of 13P180 (la11es I and 4, respecti vely). The second UP serum showed no 
spec ific reacti vity on the epidermal blot (lane 2), but did react with GST-
NC 16A 1-5 (la11 e 5). The third .BP serum reacted with epidermal BP230 (lr111 e 
J) and did not recognize 13P 180 from either the epidermal extract (/'"'" J) or 
the GST-NCI6A.I-5 preparation (!an i' 6). The two BP sera that reacted with 
GST-N I 6A 1- 5 by immunoblo tting (la11es 4 and 5) were also positi ve in the 
NC 16A ELISA , whereas the third BP serum was nega ti ve in the ELISA. The 
immunoblot labeling patterns shown here are representative of those obtained 
with the 13P sera in thi s stud y. In thi s immunoblot assay, reactivity with CST 
was elimina ted by preadsorption of t.he BP sera with recombinant CST. Shown 
to the left ore th e positions of the molecular we ight markers (in kDa) fo r a 6'){, 
polyacrylamide ge l (la11cs 1, 2, and J), whereas the markers on the ri ght (also 
in kDa) are for a 'IS'){, gel (lanes 4, 5, ond 6). 
d etection of tissue bo und immunoreac tants), the N C 16A ELISA is 
less in vasive (req uiring o nly a blood draw) and provides additional 
immun o logic info rmati o n . AU untrea ted BP patients (22 of 22) were 
posit ive in bo th o f these ossays . T hree of the 50 BP se ra in thi s study 
were negative in th e N C 16A ELISA , but w ere positive by direct IF, 
suggestin g that direct IF is th e m ore sensiti ve assay. It sho uld be kept 
in mind , however, that th ese three ELI.SA-negative se ra were obta in ed 
from l3P patients well after treatment had begun . It might turn o ut, 
after further investigation , th at re;Jctivity with N C 16A is a specifi c 
m arker fo r the initial stages of BP, and if so, the NC16A ELI.SA might 
prove to be more useful than direct IF onalysis fo r monitoring th e 
course of the disease. 
Th e BP1 80 NC16A ELISA was found to be m o re sensitive than 
any of th e other standard techniques for de tecting circulating autoanti-
bodi es in BP. Oth er m ethods that are kno wn to have a high sensitivity 
in detectin g BP au toa ntibodies include indirec t IF o n salt-split skin 
and im.munoblotting using either an epidermal extract o r recombinant 
BP1 80 . T he NC16A ELISA detec ted anti-BP1 80 autoantibodies in 
seven of th e eight BP se ra that were nega tive by indirect LF and in all 
20 BP sera that t 1il ed to react with l3P230 by immunoblotting. 
Co nversely, all three l3P se ra that were nega ti ve i11 the NC16A E LI SA 
showed reac tivity w ith BP230 by immuno blo tting, and two of these 
three se ra were positive by indi rect IF These findings corro borate 
previous reports that certai n BP sera react with BP230, but not w ith 
BP1 80 . lt is notewor:hy tlut the three sera that feU into this category 
were fi:om BP patients w ho were undergoin g th erapy for th eir disease 
at the tim e the blood samples w ere obta ined . T hese findin gs a re 
consistent wi th the hypoth es is that the earl y stages ofl3P are character-
ized by an anti-l3P1 80 auto immun e respo nse, whereas an autoantibody 
response direc ted agai nst BP230 may predo minate in the bter stages 
o f disease. Experiments des igned to test th is hypothesis are curre ntl y 
under way. 
In this study, we found that 90% of BP sera (45 of 50) reac ted with 
the GST- N C'I6A 1-5 fu sion protein by immun o bl o ttin g, a resul t that 
is in agreement w ith data fro m a similar expe rimental set-up repo rted 
by Matsumura e/ a/ ('1996). Three BP se ra fi·o m o ur study that Giled 
to react with thi s fu sion protei n by immuno blo ttin g were positi ve in 
the NC1 6A ELISA., suggesting that th e E LI SA is the more sensiti ve 
of th ese two techniqu es. Th ere was, h owever, o n e BP serum that did 
react w ith GST-NC16A 'I-5 0 11 an immun ub lot, but fe ll b e low the 
cut-off in th e N C 16A ELISA. It is possib le that antibodi es in the 
serum of thi s pati ent react w ith a denaturati o n- depe ndent e pitope 
located in th e N C 16A d o m ain . 
ln conclusio n , we ha ve developed an E LI SA systelll that provides a 
specifi c, sensiti ve, and rapid m e thod for the d .: tectio n of c irc ulatin g 
anti-BP1 80 autoantibodi es in BP. Furth er studi es w ill tes t th e usefulness 
of this assay fo r the diagnos is of o th er bullo us dermatoses characreri zed 
by autoantibodies to BP 180, including herpes gestatio nis and cicat ri c ial 
pemphigoid. 
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